The Unexpectedly Good News That Helped Regeneron Retake Its 200-Day Line
Investor's Business DailyRegeneron guided to a faster-than-expected approval timeline for a high dose of its eye drug Eylea on Thursday, and REGN stock jumped.
The post The Unexpectedly Good News That Helped Regeneron Retake Its 200-Day Line appeared first on Investor's B…